代谢性疾病和癌症期间的过氧化物酶体增殖物激活受体调节：主与仆。
Peroxisome Proliferator-Activated Receptor Modulation during Metabolic Diseases and Cancers: Master and Minions.
作者信息
Vitale Salvatore Giovanni, Laganà Antonio Simone, Nigro Angela, La Rosa Valentina Lucia, Rossetti Paola, Rapisarda Agnese Maria Chiara, La Vignera Sandro, Condorelli Rosita Angela, Corrado Francesco, Buscema Massimo, D'Anna Rosario
机构信息
Unit of Gynecology and Obstetrics, Department of Human Pathology in Adulthood and Childhood ''G. Barresi", University of Messina, Messina, Italy.
Unit of Diabetology and Endocrino-Metabolic Diseases, Hospital for Emergency Cannizzaro, Catania, Italy.
出版信息
PPAR Res. 2016;2016:6517313. doi: 10.1155/2016/6517313. Epub 2016 Dec 28.
Abstract
The prevalence of obesity and metabolic diseases (such as type 2 diabetes mellitus, dyslipidaemia, and cardiovascular diseases) has increased in the last decade, in both industrialized and developing countries. This also coincided with our observation of a similar increase in the prevalence of cancers. The aetiology of these diseases is very complex and involves genetic, nutritional, and environmental factors. Much evidence indicates the central role undertaken by peroxisome proliferator-activated receptors (PPARs) in the development of these disorders. Due to the fact that their ligands could become crucial in future target-therapies, PPARs have therefore become the focal point of much research. Based on this evidence, this narrative review was written with the purpose of outlining the effects of PPARs, their actions, and their prospective uses in metabolic diseases and cancers.
摘要
在过去十年中，肥胖症和代谢性疾病（如2型糖尿病、血脂异常和心血管疾病）在工业化国家和发展中国家的患病率均有所上升。这也与我们观察到的癌症患病率出现类似上升的情况相吻合。这些疾病的病因非常复杂，涉及遗传、营养和环境因素。大量证据表明，过氧化物酶体增殖物激活受体（PPARs）在这些疾病的发展过程中发挥着核心作用。由于其配体在未来的靶向治疗中可能至关重要，因此PPARs已成为众多研究的焦点。基于这一证据，撰写本叙述性综述的目的是概述PPARs的作用、它们的作用机制以及它们在代谢性疾病和癌症中的潜在用途。
相似文献
1
Peroxisome Proliferator-Activated Receptor Modulation during Metabolic Diseases and Cancers: Master and Minions.代谢性疾病和癌症期间的过氧化物酶体增殖物激活受体调节：主与仆。
PPAR Res. 2016;2016:6517313. doi: 10.1155/2016/6517313. Epub 2016 Dec 28.
2
Pleiotropic Actions of Peroxisome Proliferator-Activated Receptors (PPARs) in Dysregulated Metabolic Homeostasis, Inflammation and Cancer: Current Evidence and Future Perspectives.过氧化物酶体增殖物激活受体（PPARs）在代谢稳态失调、炎症和癌症中的多效性作用：当前证据与未来展望
Int J Mol Sci. 2016 Jun 24;17(7):999. doi: 10.3390/ijms17070999.
3
Biology and therapeutic applications of peroxisome proliferator- activated receptors.过氧化物酶体增殖物激活受体的生物学和治疗应用。
Curr Top Med Chem. 2012;12(6):548-84. doi: 10.2174/156802612799436669.
4
PPARs: therapeutic targets for metabolic disease.过氧化物酶体增殖物激活受体：代谢性疾病的治疗靶点
Trends Pharmacol Sci. 2005 May;26(5):244-51. doi: 10.1016/j.tips.2005.03.003.
5
Multifaceted roles of peroxisome proliferator-activated receptors (PPARs) at the cellular and whole organism levels.过氧化物酶体增殖物激活受体 (PPARs) 在细胞和整体水平上的多方面作用。
Swiss Med Wkly. 2010 Sep 15;140:w13071. doi: 10.4414/smw.2010.13071. eCollection 2010.
6
[Peroxisome proliferator-activated receptors (PPARs) in obesity and insulin resistance development].[过氧化物酶体增殖物激活受体（PPARs）在肥胖和胰岛素抵抗发展中的作用]
Rev Invest Clin. 2004 May-Jun;56(3):351-67.
7
The roles of PPARs in human diseases.过氧化物酶体增殖物激活受体（PPARs）在人类疾病中的作用。
Nucleosides Nucleotides Nucleic Acids. 2018;37(7):361-382. doi: 10.1080/15257770.2018.1475673. Epub 2018 Jul 23.
8
Peroxisome proliferators and peroxisome proliferator activated receptors (PPARs) as regulators of lipid metabolism.过氧化物酶体增殖物与过氧化物酶体增殖物激活受体（PPARs）作为脂质代谢的调节因子。
Biochimie. 1997 Feb-Mar;79(2-3):81-94. doi: 10.1016/s0300-9084(97)81496-4.
9
Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism.过氧化物酶体增殖物激活受体（PPARs）对骨代谢的调控
Fundam Clin Pharmacol. 2007 Jun;21(3):231-44. doi: 10.1111/j.1472-8206.2007.00486.x.
10
Roles of PPARs in health and disease.过氧化物酶体增殖物激活受体（PPARs）在健康与疾病中的作用。
Nature. 2000 May 25;405(6785):421-4. doi: 10.1038/35013000.
引用本文的文献
1
Role of Peroxisome Proliferator-Activated Receptor α-Dependent Mitochondrial Metabolism in Ovarian Cancer Stem Cells.过氧化物酶体增殖物激活受体 α 依赖性线粒体代谢在卵巢癌干细胞中的作用。
Int J Mol Sci. 2024 Nov 1;25(21):11760. doi: 10.3390/ijms252111760.
2
Cyclin-dependent kinase 5 (CDK5) inhibitors in Parkinson disease.细胞周期蛋白依赖性激酶 5（CDK5）抑制剂在帕金森病中的应用。
J Cell Mol Med. 2024 Jun;28(11):e18412. doi: 10.1111/jcmm.18412.
3
Peroxisome proliferator-activated receptorα/γ agonist pioglitazone for rescuing relapsed or refractory neoplasias by unlocking phenotypic plasticity.过氧化物酶体增殖物激活受体α/γ激动剂吡格列酮通过开启表型可塑性来挽救复发或难治性肿瘤。
Front Oncol. 2024 Jan 11;13:1289222. doi: 10.3389/fonc.2023.1289222. eCollection 2023.
4
VISTA+/CD8+ status correlates with favorable prognosis in Epithelial ovarian cancer.VISTA+/CD8+ 状态与上皮性卵巢癌的良好预后相关。
PLoS One. 2023 Mar 23;18(3):e0278849. doi: 10.1371/journal.pone.0278849. eCollection 2023.
5
Protein-energy malnutrition and worse outcomes after major cancer surgery: A nationwide analysis.蛋白质能量营养不良与重大癌症手术后更差的预后：一项全国性分析。
Front Oncol. 2023 Jan 17;13:970187. doi: 10.3389/fonc.2023.970187. eCollection 2023.
6
Analysis of the disease burden trend of malignant tumors of the female reproductive system in China from 2006 to 2020.分析 2006 年至 2020 年中国女性生殖系统恶性肿瘤疾病负担趋势。
BMC Womens Health. 2022 Dec 7;22(1):504. doi: 10.1186/s12905-022-02104-2.
7
circ-LIMK1 regulates cisplatin resistance in lung adenocarcinoma by targeting miR-512-5p/HMGA1 axis.环状LIMK1通过靶向miR-512-5p/HMGA1轴调控肺腺癌顺铂耐药性。
Open Med (Wars). 2022 Oct 7;17(1):1568-1583. doi: 10.1515/med-2022-0542. eCollection 2022.
8
The influence of advanced age and obesity on pregnancy course and outcome in patients with diabetes mellitus.高龄和肥胖对糖尿病患者妊娠过程及结局的影响。
Prz Menopauzalny. 2022 Sep;21(3):170-179. doi: 10.5114/pm.2022.116351. Epub 2022 May 18.
9
Circ-CSNK1G1 promotes cell proliferation, migration, invasion and glycolysis metabolism during triple-negative breast cancer progression by modulating the miR-28-5p/LDHA pathway.环状 RNA-CSNK1G1 通过调控 miR-28-5p/LDHA 通路促进三阴性乳腺癌进展中的细胞增殖、迁移、侵袭和糖酵解代谢。
Reprod Biol Endocrinol. 2022 Sep 15;20(1):138. doi: 10.1186/s12958-022-00998-z.
10
Pregnancy outcomes in women with diabetes mellitus - the impact of diabetes type and treatment.糖尿病女性的妊娠结局——糖尿病类型及治疗的影响
Prz Menopauzalny. 2022 Mar;21(1):37-46. doi: 10.5114/pm.2022.113781. Epub 2022 Feb 21.
本文引用的文献
1
Biliverdin Reductase A Attenuates Hepatic Steatosis by Inhibition of Glycogen Synthase Kinase (GSK) 3β Phosphorylation of Serine 73 of Peroxisome Proliferator-activated Receptor (PPAR) α.胆红素还原酶A通过抑制糖原合酶激酶（GSK）3β对过氧化物酶体增殖物激活受体（PPAR）α丝氨酸73的磷酸化来减轻肝脏脂肪变性。
J Biol Chem. 2016 Nov 25;291(48):25179-25191. doi: 10.1074/jbc.M116.731703. Epub 2016 Oct 10.
2
Molecular Pathways: Dietary Regulation of Stemness and Tumor Initiation by the PPAR-δ Pathway.分子途径：PPAR-δ途径对干性和肿瘤起始的饮食调控
Clin Cancer Res. 2016 Dec 1;22(23):5636-5641. doi: 10.1158/1078-0432.CCR-16-0775. Epub 2016 Oct 4.
3
How to Achieve High-Quality Oocytes? The Key Role of Myo-Inositol and Melatonin.如何获得高质量的卵母细胞？肌醇和褪黑素的关键作用。
Int J Endocrinol. 2016;2016:4987436. doi: 10.1155/2016/4987436. Epub 2016 Aug 29.
4
High-fat diet modifies the PPAR-γ pathway leading to disruption of microbial and physiological ecosystem in murine small intestine.高脂饮食改变PPAR-γ通路，导致小鼠小肠微生物和生理生态系统紊乱。
Proc Natl Acad Sci U S A. 2016 Oct 4;113(40):E5934-E5943. doi: 10.1073/pnas.1612559113. Epub 2016 Sep 16.
5
Regulation of apoptotic pathways during endometriosis: from the molecular basis to the future perspectives.子宫内膜异位症中凋亡途径的调控：从分子基础到未来展望
Arch Gynecol Obstet. 2016 Nov;294(5):897-904. doi: 10.1007/s00404-016-4195-6. Epub 2016 Sep 15.
6
Ligand-activated PPARγ downregulates CXCR4 gene expression through a novel identified PPAR response element and inhibits breast cancer progression.配体激活的PPARγ通过一个新发现的PPAR反应元件下调CXCR4基因表达，并抑制乳腺癌进展。
Oncotarget. 2016 Oct 4;7(40):65109-65124. doi: 10.18632/oncotarget.11371.
7
The PPARα Agonist Fenofibrate Improves the Musculoskeletal Effects of Exercise in Ovariectomized Rats.过氧化物酶体增殖物激活受体α激动剂非诺贝特改善去卵巢大鼠运动对肌肉骨骼的影响。
Endocrinology. 2016 Oct;157(10):3924-3934. doi: 10.1210/en.2016-1114. Epub 2016 Aug 15.
8
Heme-Regulated eIF2α Kinase Modulates Hepatic FGF21 and Is Activated by PPARβ/δ Deficiency.血红素调节的 eIF2α 激酶调节肝 FGF21 并被 PPARβ/δ 缺乏激活。
Diabetes. 2016 Oct;65(10):3185-99. doi: 10.2337/db16-0155. Epub 2016 Aug 2.
9
Pleiotropic Actions of Peroxisome Proliferator-Activated Receptors (PPARs) in Dysregulated Metabolic Homeostasis, Inflammation and Cancer: Current Evidence and Future Perspectives.过氧化物酶体增殖物激活受体（PPARs）在代谢稳态失调、炎症和癌症中的多效性作用：当前证据与未来展望
Int J Mol Sci. 2016 Jun 24;17(7):999. doi: 10.3390/ijms17070999.
10
PPAR-delta promotes survival of breast cancer cells in harsh metabolic conditions.过氧化物酶体增殖物激活受体δ（PPAR-δ）在恶劣代谢条件下促进乳腺癌细胞存活。
Oncogenesis. 2016 Jun 6;5(6):e232. doi: 10.1038/oncsis.2016.41.
Zotero 插件